Holen Sie sich die Stockscreener-App
3.81
9.72%
-0.41
Handel nachbörslich:
3.85
0.04
+1.05%
Schlusskurs vom Vortag:
$4.22
Offen:
$4.26
24-Stunden-Volumen:
6.16M
Relative Volume:
2.25
Marktkapitalisierung:
$428.55M
Einnahmen:
$1.89B
Nettoeinkommen (Verlust:
$-496.52M
KGV:
-0.8005
EPS:
-4.7598
Netto-Cashflow:
$1.40M
1W Leistung:
-35.75%
1M Leistung:
-30.85%
6M Leistung:
+12.06%
1J Leistung:
-61.63%
1-Tages-Spanne:
$3.80
$4.32
1-Wochen-Bereich:
$3.80
$5.99
52-Wochen-Spanne:
$2.095
$10.29
Evolent Health Inc Stock (EVH) Company Profile
Firmenname
Evolent Health Inc
Sektor
Branche
Telefon
571-389-6000
Adresse
1812 NORTH MOORE ST, SUITE 1705, ARLINGTON
Compare EVH vs VEEV, BTSG, HQY, TEM, TXG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVH
Evolent Health Inc
|
3.81 | 474.67M | 1.89B | -496.52M | 1.40M | -4.7598 |
VEEV
Veeva Systems Inc
|
194.46 | 30.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
71.98 | 14.31B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
99.05 | 7.91B | 1.34B | 230.70M | 440.96M | 2.6695 |
TEM
Tempus Ai Inc
|
42.91 | 7.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
45.92 | 5.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
Evolent Health Inc Stock (EVH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-11-13 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-01-10 | Eingeleitet | Needham | Buy |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-11-08 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2024-10-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-08-09 | Hochstufung | Truist | Hold → Buy |
| 2024-04-22 | Eingeleitet | Citigroup | Buy |
| 2024-03-01 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-06 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-10-16 | Eingeleitet | UBS | Buy |
| 2023-04-12 | Eingeleitet | Stephens | Overweight |
| 2022-11-01 | Eingeleitet | Truist | Hold |
| 2022-07-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-30 | Eingeleitet | Guggenheim | Buy |
| 2021-11-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-29 | Fortgesetzt | JP Morgan | Neutral |
| 2021-01-07 | Eingeleitet | BTIG Research | Buy |
| 2020-07-06 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-06-05 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2018-10-05 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-06-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-04-24 | Fortgesetzt | JP Morgan | Neutral |
| 2017-09-20 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2017-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-03-14 | Eingeleitet | Oppenheimer | Outperform |
| 2017-01-13 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-10-28 | Fortgesetzt | JP Morgan | Overweight |
| 2016-08-05 | Bestätigt | FBR Capital | Outperform |
| 2016-07-26 | Eingeleitet | Jefferies | Buy |
| 2016-07-13 | Bestätigt | FBR Capital | Outperform |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
| 2016-01-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-06-30 | Eingeleitet | Goldman | Buy |
| 2015-06-30 | Eingeleitet | JP Morgan | Overweight |
| 2015-06-30 | Eingeleitet | Leerink Partners | Outperform |
| 2015-06-30 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Evolent Health Inc Aktie (EVH) Neueste Nachrichten
Evolent Health Inc (EVH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
EVH Stock On Track To Open At Record Low – Here’s Why Keybanc Turned Cautious - Stocktwits
EVH|Evolent Health Inc|Price:4.220|Chg%:-0.425 - TradingKey
Evolent Health Inc Class A (EVH) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Evolent Health, Inc Revenue Breakdown – NYSE:EVH - TradingView
Citi Maintains Evolent Health(EVH.US) With Hold Rating, Maintains Target Price $6.75 - Moomoo
Evolent Health (EVH) Downgraded to Neutral by Citi with Revised Price Target - GuruFocus
Evolent Health, Inc Stock 12‑Month Price Target Raised to $6.06, Implies 9% Upside - TradingView
TRHC stock reflects ongoing integration as Tabula Rasa HealthCare focuses on profitability after Evo - Ad-hoc-news.de
Why Evolent Health (EVH) Stock Is Nosediving - Yahoo Finance
EVH Downgraded by Citigroup -- Price Target Raised to $6.75 - GuruFocus
EVOLENT HEALTH INC : CITIGROUP CUTS TO NEUTRAL FROM BUY; RAISES TARGET PRICE TO $6.75 FROM $5.5 - Bitget
Citi Downgrades Evolent Health(EVH.US) to Hold Rating, Raises Target Price to $6.75 - Moomoo
Evolent Health (EVH) Proxy filing Summary - Quartr
Evolent Health stock trades steady as revenue grows and margins expand - Ad-hoc-news.de
EVH Maintained by Canaccord Genuity -- Price Target Raised to $7 - GuruFocus
Avoiding Lag: Real-Time Signals in (EVH) Movement - Stock Traders Daily
ETFs Investing in Evolent Health Inc Class A Stocks - TradingView
BlackRock Portfolio Management (NYSE: EVH) discloses 5.5% Evolent Health ownership - Stock Titan
Evolent Health: The De-Risking Is Working, But Leverage Keeps Me On Hold (NYSE:EVH) - Seeking Alpha
Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now - Yahoo Finance
Evolent To Release Second Quarter 2026 Financial Results on Thur - GuruFocus
EVH5958944 Bond Profile — Key Metrics - TradingView
EVH5958944 Bond Risk Profile - TradingView
EVH5958944 Bond Coupon Profile — Rate & Payments - TradingView
Evolent Health (EVH) Stephens 26th Annual Investment Conference | NASH2024 Summary - Quartr
Evolent Health Surges 4.4%: Testing Key Resistance LevelsBullish Pattern Stocks - dars.gov.et
Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026 - StreetInsider
Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026 – Company Announcement - Financial Times
How Highmark Blue Shield is collaborating on value-based cancer care - The Business Journals
How Highmark Blue Cross Blue Shield is collaborating on value-based cancer care - The Business Journals
EVHEvolent Health Inc Dividends - Finviz
Evolent Health (EVH) CEO gets 446,102 RSUs and has shares withheld for taxes - Stock Titan
Evolent Health | 4: Statement of changes in beneficial ownership of securities-Officer Weinberg Jonathan - Moomoo
Evolent Health (EVH) General Counsel receives RSU grant with tax-withholding entry - Stock Titan
Evolent Health (EVH) president receives 302,585 RSUs in equity grant - Stock Titan
Evolent Health (EVH) grants 28,790 RSUs to Chief Accounting Officer - Stock Titan
Evolent Health focuses on value-based care as investors watch long-term growth - Ad-hoc-news.de
Evolent Health Q1 2026 slides: revenue misses forecast, leverage rises - Investing.com
Should you buy Evolent Health (EVH) after golden cross? - MSN
Should You Buy Evolent Health (EVH) After Golden Cross? - Yahoo! Finance Canada
Truist Financial Downgrades Evolent Health(EVH.US) to Hold Rating, Maintains Target Price $7 - Moomoo
Truist Financial Maintains Evolent Health(EVH.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Truist cuts Evolent Health stock rating on Medicaid headwinds By Investing.com - Investing.com South Africa
Truist cuts Evolent Health stock rating on Medicaid headwinds - Investing.com
Strength Seen in Evolent Health (EVH): Can Its 9.5% Jump Turn into More Strength? - Yahoo Finance
Enterprise value to EBIT forward of Evolent Health Inc Class A – FWB:9EH - TradingView
Price to sales forward of Evolent Health, Inc – NYSE:EVH - TradingView
Enterprise value to revenue forward of Evolent Health, Inc – NYSE:EVH - TradingView
Price to sales forward of Evolent Health Inc Class A – FWB:9EH - TradingView
Price to earnings forward of Evolent Health, Inc – NYSE:EVH - TradingView
Finanzdaten der Evolent Health Inc-Aktie (EVH)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.18%
3.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):